CST3

Across TCGA pan-cancer cohorts, CST3 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of CST3’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where CST3 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types CST3 is over-expressed in tumor, although a few such as CCRCC and HNSC show the opposite, repressed pattern.

CCRCC, HNSC, and LSCC are the cancer types where CST3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CST3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	III,IV	−1.070	<.001	9	view →
HNSC	Male	All	−0.712	<.001	8	view →
LSCC	Male	All	−0.519	<.001	8	view →
COAD	Male	All	−0.389	<.001	8	view →
PDAC	All	All	+0.456	<.001	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

CST3–CCRCC

Open the CCRCC breakdown →